Latest News & Updates
Breaking News
18 minutes ago
Pharma Now Editorial Team
Akums Gains EU GMP and UK MHRA Certifications as FY26 Revenue Reaches Rs. 4,359 Crore
Pharma Now Editorial Team
Alembic Pharma Gains US Branded Foothold with Pivya Launch as Q4 Revenue Reaches Rs. 1,848 Crore
Pharma Now Editorial Team
Novartis Gains 58% PSA Progression Risk Reduction with Pluvicto in Hormone-Sensitive Prostate Cancer
Pharma Now Editorial Team
Other trending news you may like to read
Caplin Steriles Gains US FDA Approval for Generic Foscarnet Sodium Injection in Antiviral Market
Caplin Steriles secures US FDA ANDA approval for generic foscarnet sodium injection, entering a US antiviral market worth ~$15M annually.
Pharma Now Editorial Team
Akums Gains EU GMP and UK MHRA Certifications as FY26 Revenue Reaches Rs. 4,359 Crore
Akums secures EU GMP and UK MHRA certifications while posting Rs. 4,359 crore FY26 revenue and 135% PAT growth.
Pharma Now Editorial Team
Alembic Pharma Gains US Branded Foothold with Pivya Launch as Q4 Revenue Reaches Rs. 1,848 Crore
Alembic Pharma enters US branded market with Pivya as Q4 revenue hits Rs. 1,848 crore and US formulations grow 11%.
Pharma Now Editorial Team
Novartis Gains 58% PSA Progression Risk Reduction with Pluvicto in Hormone-Sensitive Prostate Cancer
PSMAddition data show 58% lower PSA progression risk with Pluvicto in mHSPC; Novartis sNDAs filed in US, China and Japan with H2 2026 decisions expected.
Pharma Now Editorial Team
